Toosendanin inhibits osteoclast formation and alleviate postmenopausal osteoporosis by regulating the p38 signaling pathway
International Immunopharmacology · 2023
DOI: 10.1016/j.intimp.2023.109745 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Tingting Tan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, 410011 Hunan, PR China; Department of Immunology, School …. Hauptthemen laut MEDLINE: Osteoporosis, Postmenopausal, Osteoporosis, Bone Resorption. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
Disruption of the balance between osteoclasts and osteoblasts could lead to bone diseases including osteoporosis. It's well known that RANKL-RANK signaling plays a vital role in activating osteoclasts. Herein, we explored the therapeutic effects of toosendanin (TSN) in osteoporosis, showing that TSN attenuated RANKL-stimulated osteoclastogenesis and osteoclast-specific gene expression in vitro. Bioinformatics predicted that TSN could interfere p38 subunits and regulate the MAPK cascade, and we further verified and demonstrated that TSN significantly inhibited RANKL-induced p38 signaling through western blot. In ovariectomized mouse model, TSN effectively inhibited the formation of TRAP-positive osteoclasts and exhibited protective effect against bone loss. Altogether, these data indicate that TSN targeted p38 activation to inhibit osteoclastogenesis, suggesting the possible therapeutic use of TSN in osteoporosis in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, 410011 Hunan, PR China; Department of Immunology, School of Basic Medical Science, Central South University, Changsha, Hunan, P…
- Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, 410011 Hunan, PR China. Electronic address: 847092010@qq.com.
- Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, 410011 Hunan, PR China. Electronic address: chengxiang96@csu.edu.cn.
- Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, 410011 Hunan, PR China. Electronic address: ouyangzhengxiao@csu.edu.cn.
Zitieren
APA
Tan, T., Li, T., Xiang, C., & Ouyang, Z. (2023). Toosendanin inhibits osteoclast formation and alleviate postmenopausal osteoporosis by regulating the p38 signaling pathway. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.109745
Vancouver
Tan T, Li T, Xiang C, Ouyang Z. Toosendanin inhibits osteoclast formation and alleviate postmenopausal osteoporosis by regulating the p38 signaling pathway. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.109745
BibTeX
@article{Tan2023,
author = {Tan, Tingting and Li, Tao and Xiang, Cheng and Ouyang, Zhengxiao},
title = {Toosendanin inhibits osteoclast formation and alleviate postmenopausal osteoporosis by regulating the p38 signaling pathway},
journal = {International Immunopharmacology},
year = {2023},
doi = {10.1016/j.intimp.2023.109745}
}
EUVIMED